A TROP2-targeted drug helped women with hard-to-treat endometrial cancer live longer
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with endometrial cancer that progressed after chemotherapy and immunotherapy lived a median 19.0 months on sacituzumab tirumotecan, vs. 12.1…
